REDX Redx Pharma Plc

TIDMREDX

RNS Number : 7754F

Redx Pharma plc

31 October 2018

REDX PHARMA PLC

("Redx" or "the Company")

Notice of Results

Alderley Park, 31 October 2018 Redx (AIM: REDX), the drug development company focused on cancer and fibrosis, will announce its preliminary results for the year ended 30 September 2018 on Monday 19 November 2018.

For further information, please contact:

 
Redx Pharma Plc                                T: +44 1625 469 
                                                920 
Lisa Anson, Chief Executive Officer 
 
Cantor Fitzgerald Europe (Nominated Advisor &   T: +44 20 7894 
 Broker)                                         7000 
Phil Davies 
 
WG Partners LLP (Joint Broker)                 T: +44 20 3705 
                                                9330 
Claes Spång/ Chris Lee/ David Wilson 
 
FTI Consulting                                 T: +44 20 3727 
                                                1000 
Simon Conway/Stephanie Cuthbert 
 

About Redx Pharma Plc

Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORFKKDDOBDDOKN

(END) Dow Jones Newswires

October 31, 2018 03:00 ET (07:00 GMT)

Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024

Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024